Lupus & antiphospholipid syndrome
Comparison of flares in 85 patients with SLE who maintained, discontinued or reduced dose of hydroxychloroquine during a prospective study of ophthalmological screening for retinopathy (PERFOCTAPS Study)
Authors' conclusion
In this prospective study, HCQ reduction due to early suspicion of retinal toxicity was associated with a statistically significantly increased risk of disease flare.
Study context
- Population
- Patients with SLE in the prospective PERFOCTAPS Study treated with hydroxychloroquine (HCQ) for at least 5 years (98% women, mean age 40.0 years)ophthalmological abnormalities in 25 (29.4%)
- Participants
- 85 patients
- Exposure
- HCQ reduction or discontinuation after ophthalmological screening vs HCQ maintenance
- Reductionn = 20
- Discontinuationn = 5
- Outcome
- Flare occurrence (SELENA-SLEDAI Flare Index)
- Follow-up
- 2 years after HCQ reduction or discontinuation or after inclusion in the maintenance group
Methodological detailsancillary to the prospective PERFOCTAPS ophthalmological screening study, adjusted for potential confounders
- Ancillary to the prospective PERFOCTAPS ophthalmological screening study
- Adjusted for potential confounders
Main finding
As reported in the abstract
SLE flare · 2 years
Each group vs maintenanceAdjusted hazard ratio (95% CI)
Reduction
2.26(1.03–4.97)
Discontinuationno longer statistically significant
2.13(0.44–10.27)
- Flares overall
- 29 patients (34.1%)
Observational data: associations, not effects.
Original publication
Comparison of flares in 85 patients with SLE who maintained, discontinued or reduced dose of hydroxychloroquine during a prospective study of ophthalmological screening for retinopathy (PERFOCTAPS Study). Lupus Sci Med. Published 12 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →